IMUGENE LIMITED — Share Issue/Capital Change 2025

Jan 23, 2025

==> picture [177 x 31] intentionally omitted <==

ASX Announcement

24 January 2025

Release of Shares from Voluntary Escrow

In accordance with ASX Listing Rule 3.10A, Imugene Limited (ASX:IMU) (Imugene or the Company) advises that 117,697,133 fully paid ordinary shares will be released from voluntary escrow on 3 February 2025.

The escrowed shares were issued to related and unrelated party vendors of Vaxinia Pty Ltd pursuant to resolutions 1 and 2 as approved by shareholders at the Extraordinary General Meeting of the Company held on 18 November 2019.

For more information please contact:

Leslie Chong Managing Director and Chief Executive Officer info@imugene.com

General Investor Enquiries shareholderenquiries@imugene.com

Media Enquiries

Matt Wright

matt@nwrcommunications.com.au

Connect with us on LinkedIn @Imugene Limited

Follow us on Twitter @TeamImugene

Watch us on YouTube @ImugeneLimited

About Imugene (ASX:IMU)

IMUGENE LIMITED ACN 009 179 551 WWW.IMUGENE.COM info@imugene.com

==> picture [42 x 42] intentionally omitted <==

Imugene is a clinical stage immuno-oncology company developing a range of new and novel immunotherapies that seek to activate the immune system of cancer patients to treat and eradicate tumours. Our unique platform technologies seek to harness the body’s immune system against tumours, potentially achieving a similar or greater effect than synthetically manufactured monoclonal antibody and other immunotherapies.

Our pipeline includes an off-the-shelf (allogeneic) cell therapy CAR T drug azer-cel (azercabtagene zapreleucel) which targets CD19 to treat blood cancers. Our pipeline also includes multiple immunotherapy B-cell vaccine candidates and an oncolytic virotherapy (CF33) aimed at treating a variety of cancers in combination with standard of care drugs and emerging immunotherapies such as CAR T’s for solid tumours. We are supported by a leading team of international cancer experts with extensive experience in developing novel cancer therapies that are currently marketed globally.

Our vision is to help transform and improve the treatment of cancer and the lives of the millions of patients who need effective treatments. This vision is backed by a growing body of clinical evidence and peer-reviewed research. Imugene is well funded and resourced, to deliver on its commercial and clinical milestones. Together with leading specialists and medical professionals, we believe Imugene’s immunooncology therapies will become foundation treatments for cancer. Our goal is to ensure that Imugene and its shareholders are at the forefront of this rapidly growing global market.

Release authorised by the Company Secretary Imugene Limited.

IMUGENE LIMITED ACN 009 179 551

2